Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aspire Biopharma Holdings, Inc. - Warrant
(NQ:
ASBPW
)
0.0198
UNCHANGED
Streaming Delayed Price
Updated: 3:36 PM EST, Jan 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.0198
Bid (Size)
0.0196 (2,500)
Ask (Size)
0.0248 (900)
Prev. Close
0.0198
Today's Range
0.0198 - 0.0198
52wk Range
0.0100 - 0.1200
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aspire Biopharma Announces Reverse Stock Split
January 14, 2026
Via
ACCESS Newswire
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
January 07, 2026
Via
ACCESS Newswire
Performance
YTD
+6.5%
+6.5%
1 Month
-36.7%
-36.7%
3 Month
-38.3%
-38.3%
6 Month
-59.7%
-59.7%
1 Year
-73.1%
-73.1%
More News
Read More
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
December 18, 2025
Via
ACCESS Newswire
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
December 12, 2025
Via
ACCESS Newswire
Aspire Biopharma Provides Q3 2025 Business Update
December 04, 2025
Via
ACCESS Newswire
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
December 02, 2025
Via
ACCESS Newswire
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
November 26, 2025
Via
ACCESS Newswire
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
November 06, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
October 06, 2025
Via
ACCESS Newswire
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
October 03, 2025
Via
ACCESS Newswire
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
October 01, 2025
Via
ACCESS Newswire
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
September 17, 2025
Via
ACCESS Newswire
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
September 16, 2025
Via
ACCESS Newswire
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
September 03, 2025
Via
ACCESS Newswire
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
August 18, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20
August 14, 2025
Via
ACCESS Newswire
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
August 13, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
July 31, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc. Announces CEO Transition
July 30, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
July 22, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
July 09, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
June 24, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
June 10, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
May 28, 2025
Via
ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
May 20, 2025
Via
ACCESS Newswire
Frequently Asked Questions
Is Aspire Biopharma Holdings, Inc. - Warrant publicly traded?
Yes, Aspire Biopharma Holdings, Inc. - Warrant is publicly traded.
What exchange does Aspire Biopharma Holdings, Inc. - Warrant trade on?
Aspire Biopharma Holdings, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant?
The ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant is ASBPW on the Nasdaq Stock Market
What is the current price of Aspire Biopharma Holdings, Inc. - Warrant?
The current price of Aspire Biopharma Holdings, Inc. - Warrant is 0.0198
When was Aspire Biopharma Holdings, Inc. - Warrant last traded?
The last trade of Aspire Biopharma Holdings, Inc. - Warrant was at 01/15/26 03:36 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
